Haug Partners Successfully Defends Takeda’s Vyvanse® Patents Before the Federal Circuit

Today the Federal Circuit affirmed the December 27, 2022 judgement issued by Judge Stanley R. Chesler of the District of New Jersey in favor of Takeda Pharmaceuticals, protecting Takeda’s patented Vyvanse® product from generic competition.  Judge Chesler found that 14 asserted claims from 9 patents covering Vyvanse® are not invalid and infringed by Norwich Pharmaceuticals……
By: Haug Partners LLP